Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs NRx Pharmaceuticals, Inc. (NRXP)

Coherus Oncology, Inc. and NRx Pharmaceuticals, Inc. are both Biotechnology companies. NRx Pharmaceuticals, Inc. is the larger, with a market value of $106.5M against $90.0M — 1.2× the size. Coherus Oncology, Inc. has the higher net margin (−253.4% vs −691.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Coherus Oncology, Inc. leads on 10 and NRx Pharmaceuticals, Inc. on 5.

Valuation

Metric CHRS NRXP Biotechnology median
P/E n/m n/m 11.58
P/S 1.70 27.07 9.61
P/B 3.62 n/m 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m n/m 0.72
EV/Sales 4.39 20.80 9.43
Earnings yield (165.05%) (22.54%) (32.28%)
Free cash flow yield (191.02%) (22.50%) (22.27%)

Profitability

Metric CHRS NRXP Biotechnology median
Gross margin 69.81% 46.64% 68.81%
Operating margin (275.94%) (586.15%) 0.00%
Net margin (253.43%) (691.78%) 0.00%
Free cash flow margin (323.85%) (609.02%) 0.00%
Return on equity (240.54%) 131.22% (50.30%)
Return on assets (39.54%) (120.41%) (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CHRS NRXP Biotechnology median
Revenue growth (TTM) 44.36% — 6.78%
EPS growth (last fiscal year) 472.00% 43.22% 29.88%
Revenue growth, 5-year CAGR (38.41%) — 9.75%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS NRXP Biotechnology median
Debt to equity 2.08 (2.42) 0.00
Current ratio 1.51 0.86 4.74
Net debt to EBITDA 0.76 0.48 1.01

Dividend

Metric CHRS NRXP Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric CHRS NRXP Biotechnology median
Market cap 90.02m 106.50m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack